
|Articles|July 20, 2012
Keith Dunleavy, MD, Speaks About Health and Data Research
Keith Dunleavy, MD, President and CEO, Inovalon, discusses the importance of comparative effectiveness research in order to improve chronic disease management at both the individual and population levels.
Advertisement
Keith Dunleavy, MD, President and CEO, Inovalon, discusses the importance of comparative effectiveness research in order to improve chronic disease management at both the individual and population levels. Dr. Dunleavy also addresses decision support through target interventions.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Fixed-Duration Epcoritamab Plus Chemotherapy Yields Response, Remissions in DLBCL
2
EPCORE FL-1: Adding Epcoritamab to R2 Delivers “New Benchmark” in Second-Line Follicular Lymphoma
3
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
4
In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison
5












































